down arrow

NGM Biopharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Biotechnology
  • ISIN: US62921N1054
USD
1.54
-0.02 (-1.28%)

Apr 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.541.57

52 Week

0.603.75
Valuation
Technical
Day's Volume

CASH

2.39 M

Shareholding (Dec 2023)

FII

2.65%

Held by 65 FIIs

DII

49.44%

Held by 25 DIIs

Promoter

29.35%

How big is NGM Biopharmaceuticals, Inc.?

22-Jun-2025

As of Apr 04, NGM Biopharmaceuticals, Inc. has a market capitalization of 128.53 million and reported net sales of 4.42 million with a net profit of -142.38 million over the latest four quarters. Shareholder's funds are 148.64 million, and total assets amount to 168.87 million as of Dec'23.

As of Apr 04, NGM Biopharmaceuticals, Inc. has a market capitalization of 128.53 million, categorizing it as a Micro Cap company.<BR><BR>As of Apr 04, the sum of net sales for the latest four quarters is 4.42 million, while the sum of net profit for the same period is -142.38 million.<BR><BR>As of Dec'23, the shareholder's funds are reported at 148.64 million, and total assets amount to 168.87 million.

Read More

What does NGM Biopharmaceuticals, Inc. do?

22-Jun-2025

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for various diseases, with a market cap of approximately $128.53 million. As of December 2023, it reported net sales of $0 million and a net loss of $28 million.

Overview: <BR>NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases, operating within the biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Dec 2023) <BR>Most recent Net Profit: -28 Million (Quarterly Results - Dec 2023) <BR>Market-cap: USD 128.53 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 99.75% <BR>Debt Equity: -0.99 <BR>Return on Equity: -92.48% <BR>Price to Book: 0.86<BR><BR>Contact Details: <BR>Address: 333 Oyster Point Blvd, SOUTH SAN FRANCISCO CA: 94080-1978 <BR>Tel: 1 650 2435555 <BR>Fax: 1 650 5831646 <BR>Website: https://www.ngmbio.com/

Read More

Who are in the management team of NGM Biopharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of NGM Biopharmaceuticals, Inc. includes Executive Chairman William Rieflin, CEO David Woodhouse, Founder and Chief Scientific Officer Jin-Long Chen, Lead Independent Director David Goeddel, and several independent directors: Shelly Guyer, Carole Ho, Suzanne Hooper, and Mark Leschly. This team combines executive leadership with independent oversight for the company's governance and strategy.

As of March 2022, the management team of NGM Biopharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. William Rieflin, who serves as the Executive Chairman of the Board of Directors.<BR>- Mr. David Woodhouse, who is the Chief Executive Officer and a Director.<BR>- Dr. Jin-Long Chen, the Founder and Chief Scientific Officer, also serving as a Director.<BR>- Dr. David Goeddel, who is the Lead Independent Director.<BR>- Ms. Shelly Guyer, an Independent Director.<BR>- Dr. Carole Ho, an Independent Director.<BR>- Ms. Suzanne Hooper, an Independent Director.<BR>- Mr. Mark Leschly, an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Biotechnology

stock-summary
Market cap

USD 129 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

99.75%

stock-summary
Debt Equity

-0.99

stock-summary
Return on Equity

-92.48%

stock-summary
Price to Book

0.86

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2023)
Net Profit:
-28 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
29.41%
0%
29.41%
6 Months
27.27%
0%
27.27%
1 Year
-61.11%
0%
-61.11%
2 Years
-91.08%
0%
-91.08%
3 Years
-94.8%
0%
-94.8%
4 Years
-87.63%
0%
-87.63%
5 Years
-89.52%
0%
-89.52%

NGM Biopharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-54.55%
EBIT Growth (5y)
-199.25%
EBIT to Interest (avg)
-117.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.18
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
72.41%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.86
EV to EBIT
0.13
EV to EBITDA
0.13
EV to Capital Employed
-12.83
EV to Sales
-4.22
PEG Ratio
NA
Dividend Yield
99.75%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-92.48%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 45 Schemes (18.56%)

Foreign Institutions

Held by 65 Foreign Institutions (2.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is -66.67% vs -57.14% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is 3.82% vs 24.80% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.60",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-29.10",
          "val2": "-30.60",
          "chgp": "4.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.70",
          "val2": "-28.80",
          "chgp": "3.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-179,775.80%",
          "val2": "-53,460.50%",
          "chgp": "-12,631.53%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -92.04% vs -29.01% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 12.48% vs -35.25% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.40",
          "val2": "55.30",
          "chgp": "-92.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-144.30",
          "val2": "-160.30",
          "chgp": "9.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-142.40",
          "val2": "-162.70",
          "chgp": "12.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-33,177.90%",
          "val2": "-3,004.50%",
          "chgp": "-3,017.34%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQstock-summary
Dec'23
Sep'23
Change(%)
Net Sales
0.20
0.60
-66.67%
Operating Profit (PBDIT) excl Other Income
-29.10
-30.60
4.90%
Interest
0.00
0.00
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
-27.70
-28.80
3.82%
Operating Profit Margin (Excl OI)
-179,775.80%
-53,460.50%
-12,631.53%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2023 is -66.67% vs -57.14% in Sep 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2023 is 3.82% vs 24.80% in Sep 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
4.40
55.30
-92.04%
Operating Profit (PBDIT) excl Other Income
-144.30
-160.30
9.98%
Interest
0.00
0.00
Exceptional Items
-4.90
0.00
Consolidate Net Profit
-142.40
-162.70
12.48%
Operating Profit Margin (Excl OI)
-33,177.90%
-3,004.50%
-3,017.34%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -92.04% vs -29.01% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 12.48% vs -35.25% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About NGM Biopharmaceuticals, Inc. stock-summary
stock-summary
NGM Biopharmaceuticals, Inc.
Biotechnology
NGM Biopharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. The Company’s product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic steatohepatitis (NASH). NGM313 is an agonistic antibody selectively activating fibroblast growth factor receptor 1c-beta-klotho and has the potential as an insulin sensitizer for the treatment of type two diabetes and NASH. NGM386 and NGM395 are engineered variants of the human hormone known as GDF15, which is developed for the treatment of obesity. NGM120 is an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, and cancer.
Company Coordinates stock-summary
Company Details
333 Oyster Point Blvd , SOUTH SAN FRANCISCO CA : 94080-1978
stock-summary
Tel: 1 650 2435555
stock-summary
https://www.ngmbio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."